ACE and dilated cardiomyopathy: From a clinical point of view, a patient with an echocardiographic phenotype suggestive of hypertrophic, infiltrative or dilatative cardiomyopathy with preserved LVEF on 2D-TTE and LV-GLS less negative than -20% on 2D-STE analysis should be treated with cardioprotective and anti-fibrotic drugs, such as angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs) and/or aldosterone receptor antagonists.